A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone

Status Completed

Clinical Trial Summary

This is a retrospective observational real-world study, which evaluates the efficacy and safety of denosumab and non-denosumab therapies in the treatment of Chinese populations of surgically unsalvageable or severe post-surgery morbidity associated giant cell tumor of bone (GCTB), collectively referred to as unresectable GCTB, during 2013-2021 in three medical centers, serving as the external control for a single arm phase Ib/II trial on JMT103 treatment of GCTB. 301 patients were enrolled and divided into 2 groups according to their actual previous exposures. Group 1 (n=135) was denosumab group. Group 2 (n=166) included two types of exposures other than denosumab: other anti-GCTB drug therapies, or no therapy on GCTB patients. The dosage, route, frequency and other administration methods was collected according to the actual previous treatment records. The primary outcome measure was the tumor response rate [radiographic tumor response (CR/PR evaluated by ICDs or EORTC criteria) within 12 weeks, or at least 90% reduction of osteoclast like giant cells compared with baseline]. The key secondary endpoint was the tumor response rate [radiographic tumor response (CR/PR evaluated by ICDS or EORTC criteria), or at least 90% reduction of osteoclast like giant cells compared with baseline]. Other secondary Outcome Measures include: proportion of patients whose tumors was surgically resectable; median duration of tumor response (DOR), disease control rate (DCR), and time to disease progression (TTP); and types and proportion of key adverse reactions.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05402865
Study type	Observational
Source	Shanghai JMT-Bio Inc.
Contact
Status	Completed
Phase
Start date	November 10, 2021
Completion date	February 18, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00680992` - Study of Denosumab in Subjects With Giant Cell Tumor of Bone	Phase 2
Active, not recruiting	`NCT04255576` - Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone	Phase 1/Phase 2
Completed	`NCT03301857` - Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004	Phase 4
Recruiting	`NCT03295981` - Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone	Phase 3
Completed	`NCT00464620` - Trial of Dasatinib in Advanced Sarcomas	Phase 2
Recruiting	`NCT03259152` - Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone	Phase 3
Recruiting	`NCT05595603` - Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage	Phase 2
Not yet recruiting	`NCT03358212` - Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China	N/A
Completed	`NCT04002817` - Giant Cell Tumor of the Bone in Young Patients
Completed	`NCT00396279` - Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone	Phase 2
Terminated	`NCT00889590` - Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)	Phase 2
Recruiting	`NCT04586660` - Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone	Phase 4
Active, not recruiting	`NCT03449108` - LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas	Phase 2
Not yet recruiting	`NCT05813665` - A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone	Phase 3
Completed	`NCT02996734` - Giant Cell Tumor of the Extremities Treated With Surgery and/or Medical Treatment	N/A